期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 40, 期 4, 页码 549-564出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2020.07.003
关键词
Severe asthma; Anti IL-33; Benralizumab; Dupilumab; Mepolizumab; Omalizumab; Reslizumab; Tezepelumab
资金
- CRUI2020